1-14 of 14
Valerie Rouillé
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Interim Results of MRD Kinetics in the Eradic Trial from the Filo Group

Anne-Sophie Michallet, Anne Quinquenel, Remi Letestu, Tavernier Magali, Stéphane Morisset, Therese Aurran, Kamel Laribi, Florence Cymbalista, Vincent Levy, Laurence Simon, Damien Roos Weil, Veronique Leblond, Marie Sarah Dilhuydy, Cecile Tomowiak, Caroline Dartigeas, Romain Guieze, Olivier Tournilhac, Emmanuelle Ferrant, Sophie De Guibert, Pierre Feugier, Fatiha Merabet, Stéphane Lepretre, Philippe Carassou, Julie Gay, Benedicte Hivert, Luc Matthieu Fornecker, Jehan Dupuis, Lysiane Molina, Bruno Villemagne, Guillaume Cartron, Bernard Drenou, Béatrice Mahé, Omar Benbrahim, Xavier Cahu, Christelle Portois, Loic Ysebaert, Florence Nguyen Khac, Valerie Rouillé, Alain Jacques Delmer
Journal: Blood
Blood (2023) 142 (Supplement 1): 3268.
https://doi.org/10.1182/blood-2023-173341
Published: 2023
Journal Articles

A Fixed-Duration Immunochemotherapy Approach Combined with Ibrutinib in CLL Produces Deep and Sustained MRD Responses: 5.5-Year Results from the Icll-07 Filo Trial

Anne-Sophie Michallet, Rémi Letestu, Magali Le Garff-Tavernier, Carmen Aanaei, Michel Ticchioni, Marie-Sarah Dilhuydy, Stephane Morisset, Valérie Rouille, Béatrice Mahé, Kamel Laribi, Bruno Villemagne, Emmanuelle Ferrant, Olivier Tournilhac, Alain Delmer, Christelle Portois, Lysiane Molina, Véronique Leblond, Cécile Tomowiak, Sophie de Guibert, Frederique Orsini, Anne Banos, Philippe Carassou, Guillaume Cartron, Luc Mathieu Fornecker, Loic Ysebaert, Caroline Dartigeas, Margot Truchan, Jean-Pierre Vilque, Therese Aurran Schleinitz, Cymbalista Florence, Stéphane Leprêtre, Vincent Lévy, Florence Nguyen Khac, Pierre Feugier
Journal: Blood
Blood (2022) 140 (Supplement 1): 7013–7015.
https://doi.org/10.1182/blood-2022-157963
Published: 2022
Journal Articles

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation

Anne Quinquenel, Rémi Letestu, Magali Le Garff-Tavernier, Fabien Subtil, Therese Aurran-Schleinitz, Kamel Laribi, Florence Cymbalista, Vincent Levy, Laurence Simon, Damien Roos-Weil, Véronique Leblond, Marie-Sarah Dilhuydy, Caroline Dartigeas, Cecile Tomowiak, Romain Guieze, Olivier Tournilhac, Emmanuelle Ferrant, Sophie de Guibert, Pierre Feugier, Fatiha Merabet, Stephane Lepretre, Philippe Carassou, Julie Gay, Bénédicte Hivert, Luc Mathieu Fornecker, Jehan Dupuis, Lysiane Molina, Bruno Villemagne, Guillaume Cartron, Bernard Drenou, Béatrice Mahé, Omar Benbrahim, Xavier Cahu, Christelle Portois, Loic Ysebaert, Florence Nguyen Khac, Valérie Rouille, Alain Delmer, Anne-Sophie Michallet
Journal: Blood
Blood (2022) 140 (Supplement 1): 7007–7009.
https://doi.org/10.1182/blood-2022-159678
Published: 2022
Journal Articles

Blinatumomab for Patients with Richter Syndrome: Final Results of the Phase 2 Blinart Trial from the Filo Group

Romain Guieze, Loic Ysebaert, Damien Roos-Weil, Luc-Matthieu Fornecker, Emmanuelle Ferrant, Lysiane Molina, Thérèse Aurran-Schleinitz, Aline Clavert, Sophie de Guibert, Anne-Sophie Michallet, Alain Saad, Bernard Drenou, Philippe Quittet, Benedicte Hivert, Kamel Laribi, Julie Gay, Julien Broséus, Valérie Rouille, David Schwartz, Bruno Pereira, Alain Delmer, Pierre Feugier
Journal: Blood
Blood (2022) 140 (Supplement 1): 6631–6632.
https://doi.org/10.1182/blood-2022-159695
Published: 2022
Journal Articles

Blinatumomab for Patients with Richter's Syndrome: A Multicenter Phase 2 Trial from the Filo Group

Romain Guieze, Loic Ysebaert, Damien Roos-Weil, Lysiane Molina, Luc Mathieu Fornecker, Thérèse Aurran, Anne-Sophie Michallet, Emmanuelle Ferrant, Aline Clavert, Alain Saad, Sophie de Guibert, Bernard Drenou, Philippe Quittet, Bénédicte Hivert, Kamel Laribi, Julie Gay, Julien Broséus, Valérie Rouille, David Schwartz, Bruno Pereira, Alain Delmer, Pierre Feugier
Journal: Blood
Blood (2021) 138 (Supplement 1): 3570.
https://doi.org/10.1182/blood-2021-147467
Published: 2021
Journal Articles

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR

Anne-Sophie Michallet, Anne Quinquenel, Remi Letestu, Magali Le Garff-Tavernier, Fabien Subtil, Mad-Helenie Elsensohn, Therese Aurran, Kamel Laribi, Florence Cymbalista, Vincent Levy, Laurence Simon, Damien Roos-Weil, Veronique Leblond, Marie-Sarah Dilhuydy, Cécile Tomowiak, Caroline Dartigeas, Romain Guieze, Olivier Tournilhac, Emmanuelle Ferrant, Sophie de Guibert, Pierre Feugier, Fatiha Merabet, Stéphane Leprêtre, Philippe Carassou, Julie Gay, Bénédicte Hivert, Luc Mathieu Fornecker, Jehan Dupuis, Lysiane Molina, Bruno Villemagne, Guillaume Cartron, Bernard Drenou, Béatrice Mahé, Omar Benbrahim, Xavier Cahu, Christelle Portois, Loic Ysebaert, Florence Nguyen-Khac, Valérie Rouille, Alain Delmer
Journal: Blood
Blood (2021) 138 (Supplement 1): 641.
https://doi.org/10.1182/blood-2021-145624
Published: 2021
Journal Articles

A fixed-duration, measurable residual disease–guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial

Clinical Trials & Observations Brief Report
Anne-Sophie Michallet, Rémi Letestu, Magali Le Garff-Tavernier, Carmen Aanei, Michel Ticchioni, Marie-Sarah Dilhuydy, Fabien Subtil, Valerie Rouille, Beatrice Mahe, Kamel Laribi, Bruno Villemagne, Gilles Salles, Olivier Tournilhac, Alain Delmer, Christelle Portois, Brigitte Pegourie, Veronique Leblond, Cecile Tomowiak, Sophie De Guibert, Frederique Orsini Piocelle, Anne Banos, Philippe Carassou, Guillaume Cartron, Luc-Matthieu Fornecker, Loic Ysebaert, Caroline Dartigeas, Malgorzata Truchan-Graczyk, Jean-Pierre Vilque, Thérèse Aurran, Florence Cymbalista, Stéphane Lepretre, Vincent Levy, Florence Nguyen-Khac, Pierre Feugier
Journal: Blood
Blood (2021) 137 (8): 1019–1023.
https://doi.org/10.1182/blood.2020008164
Published: 2021
Includes: Supplemental data
Journal Articles

Blinatumomab after R-CHOP Debulking Therapy for Patients with Richter Transformation: Preliminary Results of the Multicenter Phase 2 Blinart Trial from the Filo Group

Romain Guieze, MD, Loic Ysebaert, MD PhD, Lysiane Molina, MD, Damien Roos-Weil, MDPhD, Anne-Sophie Michallet, MD PhD, Benedicte Hivert, MD, Julie Gay, MD, Alain Saad, MD, Luc Mathieu Fornecker, MD PhD, Julien Broséus, Valérie Rouille, Laëtitia Auvray, Alain Jacques Delmer, MD PhD, Pierre Feugier, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 4–5.
https://doi.org/10.1182/blood-2020-136667
Published: 2020
Journal Articles

Maintenance of Long-Term Undetectable Minimal Residual Disease after Combination of Ibrutinib with Abbreviated Chemotherapy in the Icll-07 Filo Trial

Anne-Sophie Michallet, MD PhD, Marie-Sarah Dilhuydy, MD, Fabien Subtil, Valérie Rouille, Beatrice Mahe, MD, Kamel Laribi, MD, Bruno Villemagne, MD, Gilles A. Salles, MD PhD, Olivier Tournilhac, Alain Jacques Delmer, MD PhD, Christelle Portois, Brigitte Pegourie, MD, Veronique Leblond, MD PhD, Cecile Tomowiak, MD, Sophie de Guibert, MD, Frederique Orsini, Anne Banos, MD, Philippe Carassou, Guillaume Cartron, Luc Mathieu Fornecker, MD PhD, Loic Ysebaert, MD PhD, Caroline Dartigeas, MD, Margot Truchan, Jean Pierre Vilque, Thérèse Aurran, MD, Florence Cymbalista, MD PhD, Stephane Lepretre, Vincent Levy, MD PhD, Florence Nguyen-Khac, MD PhD, Magali Le Garff-Tavernier, Carmen Aanaei, Michel Ticchioni, Remi Letestu, Pierre Feugier, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3038.
https://doi.org/10.1182/blood-2019-126720
Published: 2019
Journal Articles

High Rate of Complete Response (CR) with Undetectable Bone Marrow Minimal Residual Disease (MRD) after Chemo-Sparing and MRD-Driven Strategy for Untreated Fit CLL Patients: Final Results of the Icll 07 Filo Trial

Anne-Sophie Michallet, MD PhD, Marie-Sarah Dilhuydy, MD, Fabien Subtil, Valérie Rouille, Beatrice Mahe, MD, Kamel Laribi, MD, Bruno Villemagne, Gilles Andre Salles, MD PhD, Olivier Tournilhac, MD PhD, Alain Jacques Delmer, MD, Christelle Portois, Brigitte Pegourie, MD, Véronique Leblond, MD PhD, Cecile Tomowiak, MD, Sophie de Guibert, MD, Frederique Orsini, Anne Banos, MD, Philippe Carassou, Guillaume Cartron, Luc Mathieu Fornecker, Loic Ysebaert, MD PhD, Caroline Dartigeas, Margot Truchan, Thérèse Aurran, MD, Florence Cymbalista, MD, Stéphane Leprêtre, MD, Vincent Levy, MD PhD, Florence Nguyen-Khac, MD PhD, Magali Le Garff-Tavernier, Carmen Aanaei, Michel Ticchioni, Remi Letestu, Pierre Feugier
Journal: Blood
Blood (2018) 132 (Supplement 1): 1858.
https://doi.org/10.1182/blood-2018-99-111977
Published: 2018
Journal Articles

Phase II, Multicenter Trial, Exploring "Chemo-Sparing" Strategy Associating Obinutuzumab+Ibrutinib Followed By a MRD Driven Strategy, in Previously Untreated Symptomatic Medically Fit Chronic Lymphocytic Leukemia Patients (CLL): Preliminary Results of the Induction Phase of the Icll-07 Filo Study

Anne-Sophie Michallet, MD PhD, Marie-Sarah Dilhuydy, MD, Fabien Subtil, Valérie Rouille, Beatrice Mahe, MD, Kamel Laribi, Bruno Villemagne, Gilles Andre Salles, MD PhD, Olivier Tournilhac, MD PhD, Alain Jacques Delmer, MD, Christelle Portois, Brigitte Pegourie, MD, Veronique Leblond, Cecile Tomowiak, MD, Sophie de Guibert, Frederique Orsini, Anne Banos, MD, Philippe Carassou, Guillaume Cartron, Luc Mathieu Fornecker, Loic Ysebaert, MD PhD, Caroline Dartigeas, Margot Truchan, Thérèse Aurran, MD, Florence Cymbalista, MD, Stéphane Leprêtre, MD, Vincent Levy, MD PhD, Florence Nguyen Khac, Magali Le Garff-Tavernier, Carmen Aanaei, Michel Ticchioni, Remi Letestu, Pierre Feugier, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 497.
https://doi.org/10.1182/blood.V130.Suppl_1.497.497
Published: 2017
Journal Articles

Safety and Long-Term Efficacy of Maintenance Therapy with Alternating Azacytidine (AZA) and Lenalidomide (Len) Cycles in Elderly (≥ 60) Fit Patients (Pts) with Poor Prognosis AML in First Complete Remission (CR) After LIA Induction. A Phase II Multicentric GOELAMS Trial

Mathilde Hunault, MD PhD, Nathalie Maillard, MD, Aline Tanguy-Schmidt, MD, Chantal Himberlin, MD, Bachra Choufi, MD, Caroline Bonmati, MD, Marie Anne Couturier, MD, Eric Deconinck, MD PhD, Jean Pierre Marolleau, MD PhD, Frédérique Orsini-Piocelle, MD, Jacques Delaunay, MD, Emmanuelle Tavernier, MD, Christian Récher, MDPhD, Severine Lissandre, MD, Mario Ojeda-Uribe, MD, Laurence Sanhes, MD, Laurent Sutton, MD, Anne Banos, MD, Bruno Lioure, MD, Marc Bernard, MD, Didier Bouscary, MDPhD, Alain Saad, MD, Valérie Rouille, Philippe Guardiola, MD, Isabelle Luquet, MD, Marie C Bene, PharmSciD, PhD, Francois Dreyfus, MD, Jean-Yves Cahn, MD, Arnaud Pigneux, Norbert Ifrah, MD
Journal: Blood
Blood (2015) 126 (23): 3787.
https://doi.org/10.1182/blood.V126.23.3787.3787
Published: 2015
Journal Articles

Results of a Phase II Randomizing Intensified Rituximab Pre-Phase Followed By Standard FCR Vs Standard FCR in Previously Untreated Patients with Active B-Chronic Lymphocytic Leukemia (B-CLL). CLL2010FMP (for fit medically patients): A Study of the french Cooperative Group on CLL and WM (FCGCLL/MW) and the “Groupe Ouest-Est d’Etudes Des Leucémies Aigües Et Autres Maladies Du sang” (GOELAMS)

Stephane Lepretre, MD, Rémy Letestu, MD PhD, Caroline Dartigeas, MD, Hervé Maisonneuve, MD, Therese Aurran, MD, Pierre Feugier, MD PhD, Sophie de Guibert, MD, Anne Bannos, MD, Bernadette Corront, MD, Veronique Leblond, MD PhD, Alain Delmer, MD PhD, Anne Laure Gagez, PhD, Valérie Rouillé, Sandrine Vaudaux, Florence Cymbalista, MD, Guillaume Cartron, MD, Emmanuelle Ferrant, MD, Beatrice Mahe, MD, Romain Guièze, MD
Journal: Blood
Blood (2014) 124 (21): 3329.
https://doi.org/10.1182/blood.V124.21.3329.3329
Published: 2014
Journal Articles

Maintenance Therapy With Alternating Azacytidine and Lenalidomide Cycles In Elderly (≥ 60) Fit Patients (Pts) With Poor Prognosis AML In First Complete Remission (CR) After Lia Induction. A Phase II Multicentric Goelams Trial

Mathilde Hunault-Berger, MD, PhD, Edouard Randriamalala, MD, Aline Schmidt-Tanguy, MD, Chantal Himberlin, MD, Bachra Choufi, MD, Caroline Bonmati, MD, Jean Yves Cahn, MD, MD marie-Anne Couturier, Eric Deconinck, MD, PhD, Jean Pierre Marolleau, MD, PhD, Frederique orisni-Piocelle, MD, Jacques Delaunay, MD, Emmanuelle Tavernier, MD, Christian Recher, MD PhD, Severine Lissandre, MD, Mario Ojeda-Uribe, MD, Laurence Sanhes, MD, Laurent Sutton, MD, Anne Banos, MD, Bruno Lioure, MD, Thierry Lamy, MD, PhD, Didier Bouscary, MD, Alain Saad, MD, Valérie Rouille, Philippe Guardiola, MD, Isabelle Luquet, MD, MD marie-Christine Bene, Francois Dreyfus, MD, Norbert Ifrah, MD, Arnaud Pigneux, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 2691.
https://doi.org/10.1182/blood.V122.21.2691.2691
Published: 2013